Reimbursed with a limitationGenericATC L04AA32

Apremilast Devatis Starterpackung

Apremilast Devatis Starterpackung is a generic from Devatis AG and is listed on the FOPH Specialities List. Basic health insurance reimburses it within the authorised indication. The public price ranges from CHF 161.60 to CHF 161.60 depending on the pack; the co-payment is 10 per cent.

Core data

Authorisation holder
Devatis AG
ATC code
L04AA32
IT group
07.15 Immunosuppressive Stoffe
Active substances
Apremilastum
Preparation type
Generic
On the SL since
01/09/2025
Last price change
01/12/2025
Co-payment
10%

Prices per pack

The ex-factory price is the authorisation holder's price; the public price adds the distribution share and VAT. Both are FOPH maximum prices: nothing above them may be charged.

Apremilast Devatis Starterpackung Price table As of 17/09/2026
Dosage formPack sizeEx-factory pricePublic priceValid fromCat.GTIN
Filmtabl 4x10,4x20,19x30mgBlist 27 StkCHF 132.97CHF 161.6001/09/2025B7680700160018

Limitation

This preparation is reimbursed only under the conditions below. The text is the binding FOPH wording; outside those conditions basic insurance does not pay.

The FOPH publishes limitation texts in German, French and Italian only. The German wording is reproduced verbatim below.

FOPH wordingIndication 21987.XXValid from 01/09/2026

Für alle vergütungspflichtigen Indikationen gilt:
APREMILAST DEVATIS darf nicht in Kombination mit Biologika zu Lasten der OKP verordnet werden.

Die Verschreibung von APREMILAST DEVATIS für die folgenden Behandlungen kann nur durch Fachärzte der Dermatologie oder Rheumatologie oder dermatologische bzw. rheumatologische Universitätskliniken/Polikliniken erfolgen.

FOPH wordingIndication 21987.01Valid from 01/09/2026

Aktive Psoriasis-Arthritis
Behandlung erwachsener Patienten mit aktiver Psoriasis-Arthritis als Monotherapie oder in Kombination mit DMARDs (z. Bsp. Methotrexat), wenn das Ansprechen auf eine vorhergehende Therapie mit krankheitsmodifizierenden Antirheumatika (DMARDs) unzureichend gewesen ist.

FOPH wordingIndication 21987.02Valid from 01/09/2026

Schwere Plaque Psoriasis
Behandlung erwachsener Patienten mit schwerer Plaque-Psoriasis, bei denen eine Phototherapie oder eine der folgenden konventionellen systemischen Therapien (Ciclosporin, Methotrexat, Acitretin) keinen therapeutischen Erfolg gezeigt haben. Falls nach 24 Wochen kein therapeutischer Erfolg eingetreten ist, ist die Behandlung abzubrechen.

More preparations in this group

FAQ

Is Apremilast Devatis Starterpackung covered by Swiss health insurance?

Yes, but only under conditions. Apremilast Devatis Starterpackung is on the Specialities List with a limitation: basic insurance reimburses it only when the conditions in the limitation text are met, in some cases only after the insurer has granted cost approval.

What does Apremilast Devatis Starterpackung cost in Switzerland?

The public price is the maximum price set by the FOPH and for Apremilast Devatis Starterpackung ranges from CHF 161.60 to CHF 161.60 per pack. The ex-factory price ranges from CHF 132.97 to CHF 132.97. Pharmacies may not charge more, but may charge less.

Correct or complete this entry

Market access

Do you need your product on the Specialities List?

Questions about SL listing, prices or limitations? Contact Swiss Reimbursement.

  • Independent directory
  • Official FOPH data
  • Website in eight languages
Send an enquiry
Contact

About 2 minutes. No obligation.

First, a little about your business.

Your answers stay in this page until you send your enquiry.

What would you like to achieve?

Your project

Where can we reach you?

You can go back to review your answers before sending.

* Required fields
Prefer email? info@swissreimbursement.com